Canada: Federal Court Of Appeal Grants Minister Of Health The Right To Be Wrong

Last Updated: November 1 2016
Article by Will Boyer, Kiernan A. Murphy and Christopher C. Van Barr

Most Read Contributor in Canada, October 2018

In a decision1 dated October 12, 2016, the Federal Court of Appeal upheld two decisions of the minister of health (the "minister") to issue Notice of Compliances ("NOCs") to generic drug manufacturers without addressing the requirements of the Patented Medicines (Notice of Compliance) Regulations (the "NOC Regulations"). Importantly, the Court of Appeal held that the minister's decisions were to be reviewed on a standard of reasonableness, unlike prior Supreme Court jurisprudence, which had applied a correctness standard to the minister. The Court of Appeal found both of the minister's decisions to be reasonable, overturning the Federal Court's finding that they were incorrect, and effectively granting the minister the right to be wrong.

Background of the cases: the two drug submissions at issue

This appeal involved two different NOCs for different products. The first NOC was obtained by Teva Canada for a generic version of the AROMASIN product marketed by Pfizer Canada. Teva had filed an abbreviated new drug submission ("ANDS") without any data establishing bioequivalence between its generic product and AROMASIN. Instead, Teva included a certification that its drug product was identical in all respects to a previously-approved generic version of AROMASIN. Teva did not serve a Notice of Allegation on Pfizer to address the patents listed on the Patent Register against AROMASIN. Nevertheless, the minister issued an NOC to Teva.

A second NOC was issued to Hospira Healthcare Corporation ("Hospira") for its generic version of the REMICADE product marketed by Janssen Inc. ("Janssen"). Unlike AROMASIN, REMICADE is a biologic. Generic versions of biologics are approved by filing an NDS demonstrating similarity to the reference biologic drug, rather than by filing an ANDS. Hospira's NDS however did not contain any data. Hospira instead certified that it had entered into a license agreement to take over the marketing of a previously-approved generic REMICADE product. The previous generic manufacturer would no longer market the drug. Hospira did not issue a NOA to Janssen to address the patents listed against REMICADE, yet still received an NOC.

Pfizer and Janssen filed separate judicial review applications relating to the minister's decisions to issue NOCs without addressing the listed patents listed against their respective drugs.

The underlying Federal Court decisions

Pfizer's application was heard and decided first.2 The Federal Court found that the minister's decision to issue an NOC to Teva was incorrect. In determining the standard of review was correctness, the Federal Court started with the presumption that the standard is reasonableness, but found that presumption rebutted based on a contextual analysis of the case. In particular, the Federal Court found that the NOC Regulations do not afford the minister any discretion as to when to issue an NOC. Rather, that decision is mandated by the NOC Regulations and is left to the Courts during prohibition applications under those regulations. Both Teva and the minister appealed this decision, and the appeals were later consolidated.

The Federal Court's decision was released while Janssen's judicial review application remained pending. The Federal Court, on consent of the parties, set aside the decision of the minister to issue the NOC to Hospira, without prejudice to any right of appeal. Hospira and the minister appealed the judgment, and these appeals were consolidated with those in the case involving Pfizer.

Shift to a deferential standard of review

The standard of review was the critical issue before the Federal Court of Appeal. Indeed, the Federal Court had commented that the "[s]election of the appropriate standard of review in this case determines the outcome as [...] there is more than one reasonable interpretation of the NOC Regulations. However, there is only one correct interpretation."

The Federal Court of Appeal began by discounting prior jurisprudence applying a standard of correctness to decisions of the minister. The Court found, for example, that two Supreme Court decisions applying this standard to decisions of the minister made under the NOC Regulations in similar factual circumstances3 were not binding because they were decided without regard to the presumption of reasonableness later articulated by the Supreme Court. The Court of Appeal found no applicable binding jurisprudence on the standard of review and thus found that the accepted presumption of reasonableness applied.

The Court of Appeal added that the presumption arises when the administrative decision-maker is interpreting both its home statute and statutes closely connected to its function. In the Court of Appeal's view, the NOC Regulations are closely connected to the minister's function.

The Court of Appeal then disagreed with the Federal Court's conclusion that the presumption was rebutted. First, the Court of Appeal found that the NOC Regulations do not suggest that Parliament intended the minister's interpretation of the NOC Regulations be reviewed on a less deferential standard.

Next, the Court of Appeal disagreed with the Federal Court that the decision to issue an NOC is left to the Courts. The Court held that the minister has exclusive jurisdiction to determine whether a drug submission makes a direct or indirect comparison to a Canadian reference product such that the generic drug manufacturer must address any listed patents. The Courts are, the finding goes, only involved if the minister decides in its discretion that a direct or indirect comparison has been made.  They do not, the Court of Appeal found, decide during prohibition applications under the NOC Regulations whether the minister ought to have subjected the generic submission to those regulations at all.

The Court of Appeal also found, without further explanation, that the question at issue was one of mixed fact and law, and thus the reasonableness standard applied.

For these reasons, the Court of Appeal found that the deferential standard of reasonableness applied. The Court ultimately found that the minister's decision was reasonable, as the Federal Court had acknowledged. The minister's decisions were therefore reinstated such that the NOCs granted to Teva and Hospira were upheld.

Future implications

These appeals follow a recent juridical trend away from the consideration of whether decisions made by the minister of health are correct. For example, after years of consistently applying the correctness standard in judicial review applications involving data protection (with the minister accepting this standard in most cases4), the Federal Court recently accepted the minister's argument that the reasonableness standard ought to apply.5 This trend is also apparent in other analogous contexts. For example, the Supreme Court recently questioned the Patented Medicines Price Review Board's acceptance of the correctness standard.6 Subsequently, in a different case, the Court of Appeal accepted the Board's argument that the reasonableness standard applied.7

In the high-stakes world of pharmaceutical disputes, a reasonableness standard of review can have profound consequences for drug manufacturers. In the appeals discussed above, two innovative drug companies lost the opportunity to resist generic market entry under the NOC Regulations as a result of the application of the standard of review of reasonableness. This occurred despite the Federal Court's finding that the minister's decision was incorrect. The Court of Appeal's comment that those manufacturers retain the ability to sue for patent infringement may provide little comfort given the significant, and often immediate, impact of generic market entry and the well-known obstacles to obtaining interlocutory injunctions. Similar concerns apply in other regulatory niches, such as in the data protection context, where the minister decides whether an innovative drug manufacturer ought to be granted eight years of data exclusivity for an innovative drug. The minister may now be able to simply elect between various reasonable outcomes, leaving aside the previous, necessary rigour of achieving the correct outcome.


1 Teva Canada Limited v Pfizer Canada Inc., 2016 FCA 248.

2 Pfizer Canada Inc. v Canada (Health), 2014 FC 1243.

3Bristol-Myers Squibb Co. v Canada (Attorney General), 2005 SCC 26; AstraZeneca v Canada (minister of health), 2006 SCC 49.

4 See for example Takeda Canada Inc. v Canada (minister of health), 2013 FCA 13.

5 Photocure ASA v Canada (Health), 2015 FC 959.

6 Celgene Corp v. Canada (Attorney General), 2011 SCC 1.

7 Canada (Attorney General) v Sandoz Canada Inc, 2015 FCA 249.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions